Diamedica Therapeutics Inc. (DMAC) — SEC Filings
Diamedica Therapeutics Inc. (DMAC) — 21 SEC filings. Latest: 8-K (Dec 18, 2025). Includes 10 8-K, 6 10-Q, 2 DEF 14A.
View Diamedica Therapeutics Inc. on SEC EDGAR
Overview
Diamedica Therapeutics Inc. (DMAC) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 12, 2025: DiaMedica Therapeutics Inc. (DMAC) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $24.026 million, up from $16.544 million in the prior year, representing a 45.2% increase. This was driven by a substantial rise in research and development (R&D) exp
Sentiment Summary
Across 21 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 18 neutral. The dominant filing sentiment for Diamedica Therapeutics Inc. is neutral.
Filing Type Overview
Diamedica Therapeutics Inc. (DMAC) has filed 10 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 1 SC 13G with the SEC between Mar 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (21)
Risk Profile
Risk Assessment: Of DMAC's 18 recent filings, 2 were flagged as high-risk, 10 as medium-risk, and 6 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | N/A |
| Net Income | -$24.026M |
| EPS | -$0.53 |
| Debt-to-Equity | N/A |
| Cash Position | $3.326M |
| Operating Margin | N/A |
| Total Assets | $57.047M |
| Total Debt | N/A |
Key Executives
- Dr. Michael R. Rick
- Dr. David M. Rickman
- Mr. David E. Johnson
- Patrick A. Howes
- Dr. Gary S. Rabin
- Dr. Robert L. Bridges
- Dr. Rick L. Paulson
- Ms. Sarah M. Johnson
Industry Context
DiaMedica operates in the biopharmaceutical industry, focusing on developing novel therapeutics for cardiovascular and neurological diseases. The industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like DiaMedica face intense competition from larger pharmaceutical firms and other biotech startups, necessitating strong clinical trial execution and effective capital management.
Top Tags
10-Q (4) · SEC Filing (3) · financials (3) · pharmaceuticals (3) · Biotechnology (2) · R&D Spending (2) · Net Loss (2) · Pharmaceuticals (2) · 10-K (2) · DiaMedica Therapeutics (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $24.026M | Increased 45.2% for the nine months ended September 30, 2025, from $16.544 million in 2024. |
| Research and Development Expenses | $17.915M | Increased 42.3% for the nine months ended September 30, 2025, from $12.587 million in 2024. |
| General and Administrative Expenses | $7.269M | Increased 28.1% for the nine months ended September 30, 2025, from $5.675 million in 2024. |
| Marketable Securities | $51.992M | Increased from $41.122 million at December 31, 2024, indicating capital raised. |
| Common Shares Outstanding | 52,077,439 | As of November 10, 2025, reflecting recent share issuances. |
| Proceeds from Sale of Common Shares | $31.527M | Net of offering costs, for the nine months ended September 30, 2025. |
| Revenue | $0 | for the six months ended June 30, 2025, indicating no sales |
| Research and Development Expense | $1,000 | for the six months ended June 30, 2025, a decrease from the prior year |
| General and Administrative Expense | $1,000 | for the six months ended June 30, 2025, an increase from the prior year |
| Private Placement Proceeds | $1,000 | received on July 21, 2025, from issuing 1,000 shares |
| End of Reporting Period | 20250331 | Q1 2025 |
| Filing Date | 20250513 | Date of 10-Q submission |
| Fiscal Year End | 2024 | The proxy statement covers the company's performance and governance for this period. |
| Cash and Cash Equivalents | $27.1M | As of June 30, 2024, indicating liquidity. |
| R&D Expenses | $4.5M | For the three months ended June 30, 2024, showing investment in pipeline. |
Frequently Asked Questions
What are the latest SEC filings for Diamedica Therapeutics Inc. (DMAC)?
Diamedica Therapeutics Inc. has 21 recent SEC filings from Mar 2024 to Dec 2025, including 10 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of DMAC filings?
Across 21 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 18 neutral. The dominant sentiment is neutral.
Where can I find Diamedica Therapeutics Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Diamedica Therapeutics Inc. (DMAC) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Diamedica Therapeutics Inc.?
Key financial highlights from Diamedica Therapeutics Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for DMAC?
The investment thesis for DMAC includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Diamedica Therapeutics Inc.?
Key executives identified across Diamedica Therapeutics Inc.'s filings include Dr. Michael R. Rick, Dr. David M. Rickman, Mr. David E. Johnson, Patrick A. Howes, Dr. Gary S. Rabin and 3 others.
What are the main risk factors for Diamedica Therapeutics Inc. stock?
Of DMAC's 18 assessed filings, 2 were flagged high-risk, 10 medium-risk, and 6 low-risk.
What are recent predictions and forward guidance from Diamedica Therapeutics Inc.?
Forward guidance and predictions for Diamedica Therapeutics Inc. are extracted from SEC filings as they are enriched.